Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours

/in /by

Maastricht, The Netherlands, 1 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b clinical program of its lead nanomedicine candidate CriPec®-docetaxel in patients with solid tumours. This CriPec®-docetaxel program will […]

Read more

Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer

/in /by

Maastricht, The Netherlands, 24 October 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Istvan Udvaros as its Chief Medical Officer (CMO) with immediate effect. He will be responsible for the clinical strategy and development of […]

Read more

Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers

/in /by

Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific […]

Read more

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

/in /by

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures Funding used: to execute clinical phase Ib and phase IIa trials with CriPec® docetaxel to further leverage the CriPec® platform for oligonucleotides programs from proof […]

Read more

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

/in /by

Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other […]

Read more

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

/in /by

Maastricht, The Netherlands, April 28, 2016 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines. […]

Read more

Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours

/in /by

Maastricht, The Netherlands, September 29, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres […]

Read more

Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines

/in /by

Maastricht, The Netherlands, July 14, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology […]

Read more

Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications

/in /by

Maastricht, The Netherlands, 22 June 2015 – Cristal Therapeutics, a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec® platform, today announced the publication of three articles on CriPec®-based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr. Cristianne Rijcken, founder […]

Read more

Cristal Therapeutics announces formation of Scientific Advisory Board

/in /by

Maastricht, The Netherlands, 22 May 2014 – Cristal Therapeutics, today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni to its new Scientific Advisory Board. Cristal Therapeutics is a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases, such […]

Read more